What is the current stock price of Oramed Pharmaceuticals Inc. (ORMP)?

As of the latest market data, Oramed Pharmaceuticals Inc. (ORMP) is trading at $3.53. The stock has seen a gain of 0.28% today.

Does Oramed Pharmaceuticals Inc. (ORMP) pay a dividend?

Based on current data, Oramed Pharmaceuticals Inc. does not have a confirmed active dividend policy.

What is the market cap of Oramed Pharmaceuticals Inc.?

The current market capitalization of Oramed Pharmaceuticals Inc. (ORMP) is approximately unavailable.

ORMP

Oramed Pharmaceuticals Inc.·Healthcare

3.53

0.284%(+0.01)

Market Closed

3.57

1.133%(+0.04)

After Hours

Last Updated: — ET

52W L: $1.9852W H: $3.76

ORMP NEWS

defenseworld.net

6d ago

Reviewing Oramed Pharmaceuticals (NASDAQ:ORMP) & Akanda (NASDAQ:AKAN)

Akanda (NASDAQ: AKAN - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership. Risk and Volatility Akanda has a beta of

globenewswire.com

Mar 13

Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company

Position s Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds the platform's clinical development Provides Lifeward access to up to $47 million of capital HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 13, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd.

defenseworld.net

Mar 6

Head to Head Review: GN Store Nord (OTCMKTS:GNNDY) and Oramed Pharmaceuticals (NASDAQ:ORMP)

Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) and GN Store Nord (OTCMKTS:GNNDY - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations. Valuation and Earnings This table compares Oramed

defenseworld.net

Feb 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Passes Above 50 Day Moving Average – Here’s Why

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.26 and traded as high as $3.35. Oramed Pharmaceuticals shares last traded at $3.31, with a volume of 368,355 shares trading hands. Wall Street Analyst Weigh

defenseworld.net

Feb 13

Comparing QuidelOrtho (NASDAQ:QDEL) & Oramed Pharmaceuticals (NASDAQ:ORMP)

QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Profitability This table compares QuidelOrtho and Oramed Pharmaceuticals'

defenseworld.net

Jan 27

Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above Fifty Day Moving Average – Time to Sell?

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.03 and traded as high as $3.60. Oramed Pharmaceuticals shares last traded at $3.59, with a volume of 436,246 shares trading hands. Wall Street Analyst Weigh

Company Profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2007-05-01

Beta

1.25

Websitewww.oramed.com↗